<table>
<thead>
<tr>
<th>Research Ethics Committee Reference Number</th>
<th>Name of Trial</th>
<th>Date of Receipt of Valid Research Application</th>
<th>Date of First Patient Recruited</th>
<th>Benchmark Met?</th>
<th>Reason for not meeting benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>13/10/0129</td>
<td>A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects</td>
<td>25/09/2013</td>
<td>n/a</td>
<td>70-day period from Date of VRA not yet expired</td>
<td></td>
</tr>
<tr>
<td>12/10/1188</td>
<td>A Study of HS-PRI inhibitor A133387 Alone or in Combination with Abraxane Acetate in the Treatment of Castration Resistant Prostate Cancer (CRPC) no Longer Responding to Abraxane</td>
<td>01/03/2013</td>
<td>n/a</td>
<td>70-day period from Date of VRA not yet expired</td>
<td></td>
</tr>
<tr>
<td>12/10/1636</td>
<td>Validation of Sensium wireless device in a paediatric population</td>
<td>07/08/2013</td>
<td>n/a</td>
<td>70-day period from Date of VRA not yet expired</td>
<td></td>
</tr>
<tr>
<td>13/10/1126</td>
<td>Mild cognitive impairment in men following androgen deprivation therapy for prostate cancer: a longitudinal fMRI and qEEG pilot study</td>
<td>19/03/2013</td>
<td>n/a</td>
<td>70-day period from Date of VRA not yet expired</td>
<td></td>
</tr>
<tr>
<td>11/NE/0177</td>
<td>A Phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis</td>
<td>18/08/2013</td>
<td>n/a</td>
<td>70-day period from Date of VRA not yet expired</td>
<td></td>
</tr>
<tr>
<td>12/LO/0696</td>
<td>Glycaemic Index testing of carbohydrate containing foods using a standardised method</td>
<td>23/05/2013</td>
<td>28/05/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/LO/0552</td>
<td>SinuSys Patency of Maxillary Sinus Ostia Study</td>
<td>05/06/2013</td>
<td>12/06/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/NW/0711</td>
<td>A Prospective Multicentre Clinical Surveillance Study To Evaluate The Stability, Efficacy And Safety Of The Furlong Evolution? Hip Stem In Primary Total Hip Arthropathy</td>
<td>06/06/2013</td>
<td>17/06/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/10/0768</td>
<td>Proportion of excision volume and length after treatment for cervical intra-epithelial lesions: cervical healing, quality of regenerated tissue, immunology and pregnancy outcome</td>
<td>23/04/2013</td>
<td>07/05/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/LO/1156</td>
<td>A Phase III, Randomised, Double-blind , Controlled Study of Cabozantinib (XL184) vs Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abraxane or MDV3100?</td>
<td>06/02/2013</td>
<td>21/02/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>13/10/0425</td>
<td>A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 and Ribavirin (RBV) in Treatment-Naive Adults with Genotype 1a Chronic?</td>
<td>18/04/2013</td>
<td>03/05/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>09/H0707/41</td>
<td>Investigation of the physiological breakdown of glucagon-like peptide-1 (glp-1)</td>
<td>20/11/2012</td>
<td>05/12/2012</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/SC/0380</td>
<td>A Phase 3 Blinded Randomized Study of Peginterferon Lambda 1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir?</td>
<td>29/08/2013</td>
<td>16/09/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/NE/0266</td>
<td>A phase 3 multicenter, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 weeks in treatment naive and treatment experienced subjects with chronic genotype 2 or 3 HCV infection</td>
<td>09/10/2012</td>
<td>29/10/2012</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>11/10/0035</td>
<td>Monitoring the health of children taking allergy medications (STOP)</td>
<td>07/11/2012</td>
<td>27/11/2012</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>11/10/0063</td>
<td>The acute effects of dietary components on central blood pressure</td>
<td>18/02/2013</td>
<td>12/03/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/10/1178</td>
<td>Mechanisms of interplay between allergy and viruses in asthma: A human model of rhinovirus induced acute asthma exacerbations</td>
<td>23/01/2013</td>
<td>18/02/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>11/10/0223</td>
<td>A combined retrospective and prospective post marketing surveillance study in patients using Temperature controlled Laminar Airflow (TLA)</td>
<td>24/04/2013</td>
<td>23/05/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>11/10/1385</td>
<td>A phase 1 study to assess the safety, tolerability and pharmacokinetic profile of bocprevir and sidelenafi when dosed separately and together in healthy male volunteers (the bocprevir and sidelenafi PK study)</td>
<td>15/11/2012</td>
<td>15/12/2012</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/10/1289</td>
<td>Pre-Exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or deferred daily Truvada for HIV negative gay men</td>
<td>12/02/2013</td>
<td>14/03/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>12/10/1570</td>
<td>Neuroinflammation in HIV individuals stable on CART: a [11C] PBR28 PET CT study</td>
<td>25/02/2013</td>
<td>28/03/2013</td>
<td>Yes Benchmark met</td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>Status</td>
<td>Date</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A psycho-educational intervention to improve family mental health and child educational outcomes following admission to paediatric intensive care: A Pilot Study</td>
<td>Benchmark met</td>
<td>13/11/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A phase II trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer (ARISTOTLE)</td>
<td>Benchmark met</td>
<td>15/02/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment Na?ve Subjects with Chronic HCV Infection</td>
<td>Benchmark met</td>
<td>10/01/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The role of 123I SPECT-CT scintigraphy as a novel diagnostic test in patients with liver tumours</td>
<td>Benchmark met</td>
<td>01/12/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase III, randomised, open label, active controlled study of an interferon-free regimen of BI201727 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylated interferon and ribavirin in treatment na?ve?</td>
<td>Benchmark met</td>
<td>03/05/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal Embolisation in Transcatheter Aortic Valve Implantation: Pilot Study</td>
<td>Benchmark met</td>
<td>17/05/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HERO: Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial</td>
<td>Benchmark met</td>
<td>11/10/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The effectiveness and acceptability of a computerised self-help guide for women with vaginismus</td>
<td>Benchmark met</td>
<td>09/05/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Na?ve and Treatment Experienced Subjects with Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Infection</td>
<td>Benchmark met</td>
<td>17/12/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE-EPIC: Enhancing the effects of pulmonary rehabilitation in COPD</td>
<td>Benchmark met</td>
<td>29/10/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reducing with Mifepristone vascular lesions in T1DM (The REMOVAL Study)</td>
<td>Benchmark met</td>
<td>12/12/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies</td>
<td>Benchmark met</td>
<td>27/11/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characterisation and establishment of methods to measure Male Urethral Immune Response (MUIR)</td>
<td>Benchmark met</td>
<td>22/12/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients?</td>
<td>Benchmark met</td>
<td>13/06/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enhanced Control of Hypertension and Thrombolysis Stroke Trial (ENCHANTED)</td>
<td>Benchmark met</td>
<td>05/09/2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena)</td>
<td>Benchmark met</td>
<td>13/05/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/NS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV Infection</td>
<td>Benchmark met</td>
<td>25/01/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A randomised controlled trial of internet based cognitive behavioural therapy (CBT) versus treatment as usual (TAU) for pregnant women with symptoms of depression</td>
<td>Benchmark met</td>
<td>10/06/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preventing enduring behavioural problems in young children through early psychological intervention: A pilot study (Healthy Start Happy Start: Helping with Children’s Behaviour)</td>
<td>Benchmark met</td>
<td>07/06/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Duzdrex Versus Lucentis in Patients with Branch Retinal Vein Occlusion</td>
<td>Benchmark met</td>
<td>03/06/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measures in sleeve gastrectomy after staple line reinforcement: Seaguard vs Duett TKS</td>
<td>Benchmark met</td>
<td>22/05/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination FC plus Ofatumumab at Standard or Mega dose for the treatment of CLL</td>
<td>Benchmark met</td>
<td>25/04/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase I Study Of Eversitimus Therapy Before Nephrectomy In Metastatic Renal Cell Cancer</td>
<td>Benchmark met</td>
<td>24/04/2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Study Description</td>
<td>Start Date</td>
<td>End Date</td>
<td>Eligibility Notes</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>----------</td>
<td>-----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>09/04/2013</td>
<td>A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>13/03/2013</td>
<td>A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>05/03/2013</td>
<td>Randomized phase II study of BI2235 or everolimus in advanced pancreatic neuroendocrine tumors</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>27/02/2013</td>
<td>The effect of a low-carbohydrate, ketogenic diet versus a low-fat diet on weight loss and appetite regulation in type 2 diabetics</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>28/02/2013</td>
<td>A randomised phase III trial of single fraction radiotherapy compared to multifraction radiotherapy in patients with metastatic spinal cord compression (SCORAD III)</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>26/02/2013</td>
<td>Effect of Nike FuelBand on Exercise and Function in Claudicants</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>23/03/2013</td>
<td>ACR/EULAR endorsed study to develop new classification and diagnostic criteria for primary systemic vasculitis</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>14/01/2013</td>
<td>Sample collection study to investigate the role of Homologous Recombination Deficiency in platinum sensitivity in recurrent high grade serous ovarian cancer</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>10/12/2012</td>
<td>A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>16/11/2012</td>
<td>Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. ICE CREAM: The Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients?</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>01/11/2012</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Benudamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia</td>
<td></td>
<td></td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>12/12/2012</td>
<td>Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA)</td>
<td>12/8/2012</td>
<td>28/02/2013</td>
<td>Eligible patients not yet identified &amp;/or consented in clinics</td>
<td></td>
</tr>
<tr>
<td>15/04/2013</td>
<td>Venous Insufficiency and Neuromuscular Stimulation</td>
<td>04/07/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>22/04/2013</td>
<td>An Observational Open-label multicentre, prospective follow-up study of patients with Chronic Myeloid Leukaemia (CML) treated with nilotinib in the ENEST1st (CAMN107EIC01) Study</td>
<td>15/07/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>05/01/2013</td>
<td>A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAAs) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with?</td>
<td>09/10/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>02/10/2012</td>
<td>The effect of exercise on wound healing in venous leg ulcers</td>
<td>02/02/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>02/05/2013</td>
<td>A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present?</td>
<td>02/05/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>13/10/2012</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia</td>
<td>13/10/2012</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>17/05/2013</td>
<td>A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Eltrombopag/Omacitinib/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 17</td>
<td>17/05/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>21/08/2013</td>
<td>Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA)</td>
<td>10/12/2012</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>20/02/2013</td>
<td>Ward Randomised Case-crossover trial of a new Personal Hand Hygiene Device by ORBEL</td>
<td>20/02/2013</td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>13/10/2012</td>
<td>A Companion Trial to Study GS-US-332-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic?</td>
<td>13/10/2012</td>
<td></td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
12/10/0777 Maraviroc Switch Central Nervous System Study (March CNS) Substudy - a substudy of MARCH 19/02/2013 29/08/2013 No Eligible patients not yet identified &/or consented in clinics

12/SC/0435 Efficacy and safety of 3 doses of S38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10mg/day) in patients with moderate Alzheimer’s Disease 19/10/2012 20/05/2013 No Eligible patients not yet identified &/or consented in clinics

10/H1005/6 Does co-carvedilol treatment in combination with routine NHS occupational and physical therapy, delivered early after stroke within a stroke rehabilitation service, improve functional recovery including walking ability and arm function? 04/09/2012 30/08/2013 No Eligible patients not yet identified &/or consented in clinics

13/L0/0097 A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects? 16/05/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

13/SC/0174 A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like molecular 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC) 16/05/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/LO/1762 Left ventricular MultiSpot Pacing for CRT (iSpot) 02/05/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

11/EM/0450 A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (Pa022) 02/04/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

11/LO/0185 PROMs Prostate MRI Imaging Study (MRC PR11) - Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterisation of Prostate Cancer 01/04/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/NE/0342 A Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH) - A Multicentre, Randomized, Double Blind, Placebo-Controlled study, with an adaptive design to allow for? 11/03/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/LO/1358 Randomized, Double-Blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC In Patients With Metastatic Colorectal Cancer Refractory To Standard Chemotherapies 11/03/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

13/EE/0010 A phase I clinical trial to assess the safety and immunogenicity of three HIV GTU MultivH DNA immunisations administered via the Intramuscular, Intradermal and Transcutaneous routes in healthy male and female volunteers - CUTHIVAC 0017 08/03/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

09/H0707/88 A Placebo Controlled study, with an adaptive design to allow for? 12/02/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

10/H107/46 Non cirrhotic portal hypertension: An emerging clinically significant liver disease in patients with human immunodeficiency virus 04/02/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/LO/0486 An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602: A Recombinant Factor Villa Variant (813), in adult Hemophilia A and B Subjects with or without inhibitors 21/11/2012 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

09/H0406/106 Ofatumumab versus Rituximab Salvage Chemimunnotherapy followed by ASCT in Relapsed or Refractory DLBCL 10/10/2012 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

11/NW/0075 Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal nodal R2 involvement 10/10/2012 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/WS/0180 A multi-centre, two stage, phase II study, evaluating the efficacy of oral BEZA235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR? 05/10/2012 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/EE/0055 Research Project In Association with Protocol WN25 203 "CSF sample retention for biomarker assay development" 08/08/2012 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/LO/1769 Exploring the Physiological role of proportionate in glucose homeostasis in man 15/01/2013 20/01/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

13/LO/0535 A Randomized Controlled Phase 3 Study of Oral Pacitinate versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polyclonemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis 23/05/2013 30/09/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

11/WS/0090 A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the uterine 08/03/2013 30/08/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16 01/02/2013 01/08/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

A randomized multi-center study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum sensitive ovarian cancer AG0-OGAV-ID: AG0-DV3R OP-A (DESKTOP II) 10/10/2012 25/05/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IROS) 06/06/2012 06/02/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy 10/12/2012 28/09/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

A phase III randomised trial of adjuvant chemotherapy versus observation in transitional cell carcinoma of the upper tract 23/05/2012 11/07/2013 No Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemicitabine in Combination With TH-302 Compared With Gemicitabine in Combination With Placebo in Previously Untreated Subjects 11/07/2013 No NHS permissions and/or contract negotiation

Multi-Channel Near Infrared Spectroscopy to Detect Spreading Depolarisations in Brain Injured Patients 01/07/2013 No NHS permissions and/or contract negotiation

A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II) 12/11/2012 28/01/2013 No NHS permissions and/or contract negotiation

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 (SAPPHIRE-II) 13/11/2012 05/02/2013 No NHS permissions and/or contract negotiation

Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging (DISCOVAR) 04/12/2013 27/02/2013 No NHS permissions and/or contract negotiation

A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II) 12/11/2012 28/01/2013 No NHS permissions and/or contract negotiation

A Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs Standard Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and Hypopharyngeal Cancers 15/02/2013 28/05/2013 No NHS permissions and/or contract negotiation

A two-centre randomised controlled trial investigating the effect of remote ischaemic preconditioning (RIPC) on blood and myocardial biomarkers of stress and injury-related signalling in patients having isolated coronary artery bypass grafting? 07/11/2012 25/02/2013 No NHS permissions and/or contract negotiation

A phase II, open-label, multi-centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicity, to a fixed dose of tenofovir/emtricitabine 10/10/2012 04/02/2013 No NHS permissions and/or contract negotiation

A Multi-Centre, Open-Label, Adaptive, Randomised Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naive Patients? 10/10/2012 26/02/2013 No NHS permissions and/or contract negotiation

A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Previously Untreated Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer 12/10/2012 19/04/2013 No NHS permissions and/or contract negotiation

Efficacy of Metformin in Pregnant Obese Women, a Randomised Controlled Trial (EMPOWaR) 24/06/2012 31/01/2013 No NHS permissions and/or contract negotiation

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (SuperT) 28/11/2012 15/07/2013 No NHS permissions and/or contract negotiation
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>Sponsor Amendments Required</th>
<th>Study Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/LO/1465</td>
<td>MAPPING: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and FEC-PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma</td>
<td>27/09/2011</td>
<td>19/03/2013</td>
<td>No</td>
<td>NHS permissions and/or contract negotiation</td>
</tr>
<tr>
<td>11/SC/0454</td>
<td>A phase IIIb parallel group, open label study of pegylated interferon alfa2a monotherapy (PEGIFN, Ro 258310) compared to untreated control in children with HBsAg positive chronic hepatitis B</td>
<td>08/10/2012</td>
<td>04/04/2013</td>
<td>No</td>
<td>Sponsor amendments delayed identification and consent of patients / study falls under definition of rare disease</td>
</tr>
<tr>
<td>12/WA/0064</td>
<td>A performance evaluation study of Urosens mcm5 Elisa test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy</td>
<td>28/03/2013</td>
<td>02/07/2013</td>
<td>No</td>
<td>Sponsor delays in study initiation</td>
</tr>
<tr>
<td>12/LO/0115</td>
<td>A phase I clinical trial investigating immunisation strategies using DNA, MVA and rgp140 adjuvanted with GLAAs to maximise antibody responses</td>
<td>22/03/2013</td>
<td>28/06/2013</td>
<td>No</td>
<td>Sponsor delays in study initiation</td>
</tr>
<tr>
<td>12/WS/0039</td>
<td>A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capcitabine (CI)</td>
<td>28/11/2012</td>
<td></td>
<td>No</td>
<td>Sponsor submitted 4 amendments following submission of VRA</td>
</tr>
<tr>
<td>12/LO/1174</td>
<td>AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSX2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary</td>
<td>15/11/2012</td>
<td>04/02/2013</td>
<td>No</td>
<td>Study falls under definition of rare disease</td>
</tr>
<tr>
<td>12/NW/0251</td>
<td>A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase III study comparing treatment with 177Lu-DOTA-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive?</td>
<td>29/09/2012</td>
<td>08/02/2013</td>
<td>No</td>
<td>Study falls under definition of rare disease</td>
</tr>
<tr>
<td>12/EE/0374</td>
<td>A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomycin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile?</td>
<td>09/11/2012</td>
<td></td>
<td>No</td>
<td>Study suspended by sponsor</td>
</tr>
<tr>
<td>12/LO/0355</td>
<td>192024-041D - A Multicenter, Paired-eye Comparison, Dose-escalation, Single Dose, 24-Month Study of Safety and Efficacy of Bimatoprost Preservative Free Intracameral Drug Delivery System (Bimatoprost PF IC DDS) in Patients With Open-Angle Glaucoma</td>
<td>18/06/2012</td>
<td></td>
<td>No</td>
<td>Study was withdrawn by sponsor</td>
</tr>
</tbody>
</table>